FDA
-
-
-
-
-
-
-
Silverback (SBTX) Reports FDA's Acceptance of ARS Pharmaceuticals’ NDA for neffy
-
-
-
-
-
-
-
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric
-
322,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

